Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5248-5256

  Minami, Takae ^a   Adachi, Masaaki ^a,b   Kawamura, Rina ^a   Zhang, Yubin ^a   Shinomura, Yasuhisa ^a   Imai, Kohzoh ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; BORTEZOMIB; DNA FRAGMENT; FREE RADICAL; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; STRESS ACTIVATED PROTEIN KINASE; SULINDAC; SYNAPTOPHYSIN; SYNAPTOPHYSIN INHIBITOR; TOCOPHEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CHEMOPROPHYLAXIS; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DNA HISTONE INTERACTION; DRUG METABOLISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DEATH; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA DAMAGE; DRUG INTERACTIONS; HUMANS; MICE; MICE, NUDE; OXIDATIVE STRESS; PYRAZINES; REACTIVE OXYGEN SPECIES; SULINDAC; TRANSPLANTATION, HETEROLOGOUS;

EID: 22344434243     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0085     Document Type: Article

References (36)

1. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res 1995;55:1464-72.
2. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res 1996;56: 710-4.
3. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7.
4. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
5. Bresalier RS. Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers. Gastroenterology 2002;123:379-81.
6. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57:2452-9.
7. Subbegowda R, Frommel TO. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res 1998; 58:2772-6.
8. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15: 2742-4.
9. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
10. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-9.
11. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998;95:681-6.
12. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-14.
13. Yasui H, Adachi M, Imai K. Combination of tumor necrosis factor-α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer 2003;97: 1412-20.
14. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-9.
15. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor Bortezomib inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
17. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
18. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor Bortezomib-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9: 1145-54.
19. Papageorgiou A, Lashinger L, Millikan R, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004;64:8973-9.
20. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004;22:3720-5.
21. 2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
22. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
23. Chung YM, Bae YS, Lee SY. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicytate-induced apoptosis. Free Radic Biol Med 2003;34:434-42.
24. Fernandes E, Toste SA, Lima JL, Reis S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic Biol Med 2003;35:1008-17.
25. Tatebe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance proteins MRP1 and MRP3 and γ-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun 2002;290:1427-33.
26. Becker LB, vanden Hoek TL, Shao ZH, Li CQ, Schumacker PT. Generation of superoxide in cardiomyocytes during ischemia before reperfusion. Am J Physiol 1999;277:2240-6.
27. Niess AM, Passek F, Lorenz I, et al. Expression of the antioxidant stress protein heme oxygenase-1 (HO-1) in human leukocytes. Free Radic Biol Med 1999;26: 184-92.
28. Elbirt KK, Whitmarsh AJ, Davis RJ, Bonkovsky HL. Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases. J Biol Chem 1998; 273:8922-31.
29. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5.
30. Sekiguchi M, Tsuzuki T. Oxidative nucleotide damage: consequences and prevention. Oncogene 2002; 21:8895-904.
31. Helbock HJ, Beckman KB, Ames BN. 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol 1999;300:156-66.
32. Blau S, Rubinstein A, Bass P, Singaram C, Kohen R. Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Mol Cell Biochem 1999;194:185-91.
33. Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004;295:555-66.
34. Chen HW, Chien CT, Yu SL, Lee YT, Chen WJ. Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70. Br J Pharmacol 2002; 137:771-81.
35. Rice PL, Kelloff J, Sullivan H, et al. Sulindac metabolites induce caspase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Ther 2003;2:885-92.
36. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209-19.